S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
Would Buffett Approve of This Growth Strategy? (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
Stock market today: Global shares mostly fall over China worries
Would Buffett Approve of This Growth Strategy? (Ad)
How You Can Reverse Engineer Michael Burry's Latest Buy
Target Will Close 9 Stores Across 4 States Due to Ongoing Crime That's 'Threatening the Safety' of Customers and Employees
The Strategic Gold Play You Haven't Heard About (Ad)
Video: Jack in the Box Employee Shoots at Customer Over Alleged Missing Curly Fries, Family Files Lawsuit
3 Mid-Cap Momentum Plays to Ride Into Q4
S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
Would Buffett Approve of This Growth Strategy? (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
Stock market today: Global shares mostly fall over China worries
Would Buffett Approve of This Growth Strategy? (Ad)
How You Can Reverse Engineer Michael Burry's Latest Buy
Target Will Close 9 Stores Across 4 States Due to Ongoing Crime That's 'Threatening the Safety' of Customers and Employees
The Strategic Gold Play You Haven't Heard About (Ad)
Video: Jack in the Box Employee Shoots at Customer Over Alleged Missing Curly Fries, Family Files Lawsuit
3 Mid-Cap Momentum Plays to Ride Into Q4
S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
Would Buffett Approve of This Growth Strategy? (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
Stock market today: Global shares mostly fall over China worries
Would Buffett Approve of This Growth Strategy? (Ad)
How You Can Reverse Engineer Michael Burry's Latest Buy
Target Will Close 9 Stores Across 4 States Due to Ongoing Crime That's 'Threatening the Safety' of Customers and Employees
The Strategic Gold Play You Haven't Heard About (Ad)
Video: Jack in the Box Employee Shoots at Customer Over Alleged Missing Curly Fries, Family Files Lawsuit
3 Mid-Cap Momentum Plays to Ride Into Q4
S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
Would Buffett Approve of This Growth Strategy? (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
Stock market today: Global shares mostly fall over China worries
Would Buffett Approve of This Growth Strategy? (Ad)
How You Can Reverse Engineer Michael Burry's Latest Buy
Target Will Close 9 Stores Across 4 States Due to Ongoing Crime That's 'Threatening the Safety' of Customers and Employees
The Strategic Gold Play You Haven't Heard About (Ad)
Video: Jack in the Box Employee Shoots at Customer Over Alleged Missing Curly Fries, Family Files Lawsuit
3 Mid-Cap Momentum Plays to Ride Into Q4

Biogen (BIIB) Stock Forecast, Price & News

$257.52
-0.53 (-0.21%)
(As of 09/27/2023 ET)
Compare
Today's Range
$255.16
$261.38
50-Day Range
$253.30
$277.00
52-Week Range
$250.31
$319.76
Volume
806,414 shs
Average Volume
769,809 shs
Market Capitalization
$37.29 billion
P/E Ratio
14.02
Dividend Yield
N/A
Price Target
$325.36

Biogen MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.81 Rating Score
Upside/​Downside
26.3% Upside
$325.36 Price Target
Short Interest
Healthy
2.23% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.45
Upright™ Environmental Score
News Sentiment
1.00mentions of Biogen in the last 14 days
Based on 18 Articles This Week
Insider Trading
Selling Shares
$139,037 Sold Last Quarter
Proj. Earnings Growth
6.89%
From $15.25 to $16.30 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.83 out of 5 stars

Medical Sector

62nd out of 976 stocks

Biological Products, Except Diagnostic Industry

7th out of 159 stocks


BIIB stock logo

About Biogen (NASDAQ:BIIB) Stock

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It also provides RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, immunology related diseases, neurovascular disorders, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. Biogen Inc. has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

BIIB Price History

BIIB Stock News Headlines

Are Gene Therapy Stocks The Market's Next Big Winners? (BIIB)
Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.
Reviewing Biogen (NASDAQ:BIIB) and Beam Therapeutics (NASDAQ:BEAM)
Windfall profits possible with this under-the-radar lithium stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
Windfall profits possible with this under-the-radar lithium stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
Biogen Inc. (BIIB) Stock Moves -0.19%: What You Should Know
3 Biotech Gainers to Consider
Biogen Inc BIIB Stock Quote
See More Headlines
Receive BIIB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biogen and its competitors with MarketBeat's FREE daily newsletter.

BIIB Company Calendar

Last Earnings
7/25/2023
Today
9/28/2023
Next Earnings (Estimated)
10/24/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:BIIB
CUSIP
09062X10
Employees
8,725
Year Founded
1978

Price Target and Rating

Average Stock Price Forecast
$325.36
High Stock Price Forecast
$381.00
Low Stock Price Forecast
$269.00
Forecasted Upside/Downside
+26.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.81
Research Coverage
27 Analysts

Profitability

Net Income
$3.05 billion
Pretax Margin
31.30%

Debt

Sales & Book Value

Annual Sales
$9.97 billion
Cash Flow
$21.73 per share
Book Value
$92.97 per share

Miscellaneous

Free Float
143,954,000
Market Cap
$37.29 billion
Optionable
Optionable
Beta
0.13

Social Links

(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Christopher A. Viehbacher (Age 62)
    Pres, CEO & Director
    Comp: $487.94k
  • Mr. Michael R. McDonnell CPA (Age 59)
    Exec. VP & CFO
    Comp: $2.12M
  • Ms. Nicole Murphy
    Head of Pharmaceutical Operations & Technology
  • Ms. Susan H. Alexander Esq.Ms. Susan H. Alexander Esq. (Age 66)
    Exec. VP, Chief Legal Officer & Sec.
    Comp: $2.2M
  • Dr. Ginger Gregory (Age 55)
    Exec. VP & Chief HR Officer
    Comp: $1.59M
  • Ms. Robin C. Kramer (Age 57)
    Sr. VP & Chief Accounting Officer
  • Mr. Charles E. Triano
    Sr. VP & Head of Investor Relations
  • Ms. Natacha Gassenbach
    Chief Communication Officer & Head of Corp. Affairs
  • Mr. Adam Keeney Ph.D.
    Exec. VP & Head of Corp. Devel.
  • Ms. Alisha A. Alaimo
    Pres & Head of North America













BIIB Stock - Frequently Asked Questions

Should I buy or sell Biogen stock right now?

27 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last twelve months. There are currently 5 hold ratings and 22 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BIIB shares.
View BIIB analyst ratings
or view top-rated stocks.

What is Biogen's stock price forecast for 2023?

27 equities research analysts have issued twelve-month price targets for Biogen's shares. Their BIIB share price forecasts range from $269.00 to $381.00. On average, they expect the company's share price to reach $325.36 in the next year. This suggests a possible upside of 26.3% from the stock's current price.
View analysts price targets for BIIB
or view top-rated stocks among Wall Street analysts.

How have BIIB shares performed in 2023?

Biogen's stock was trading at $276.92 on January 1st, 2023. Since then, BIIB shares have decreased by 7.0% and is now trading at $257.52.
View the best growth stocks for 2023 here
.

When is Biogen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, October 24th 2023.
View our BIIB earnings forecast
.

How were Biogen's earnings last quarter?

Biogen Inc. (NASDAQ:BIIB) issued its quarterly earnings data on Tuesday, July, 25th. The biotechnology company reported $4.02 earnings per share for the quarter, beating analysts' consensus estimates of $3.77 by $0.25. The biotechnology company earned $2.46 billion during the quarter, compared to the consensus estimate of $2.36 billion. Biogen had a net margin of 26.72% and a trailing twelve-month return on equity of 17.33%. The business's quarterly revenue was down 5.1% on a year-over-year basis. During the same quarter last year, the business posted $5.25 EPS.
Read the conference call transcript
.

What guidance has Biogen issued on next quarter's earnings?

Biogen issued an update on its FY 2023 earnings guidance on Tuesday, July, 25th. The company provided EPS guidance of $15.00-$16.00 for the period, compared to the consensus EPS estimate of $15.42. The company issued revenue guidance of -.

What is Michel Vounatsos' approval rating as Biogen's CEO?

394 employees have rated Biogen Chief Executive Officer Michel Vounatsos on Glassdoor.com. Michel Vounatsos has an approval rating of 86% among the company's employees. 72.0% of employees surveyed would recommend working at Biogen to a friend.

What other stocks do shareholders of Biogen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Amgen (AMGN), Walt Disney (DIS), Intel (INTC), Micron Technology (MU) and Boeing (BA).

What is Biogen's stock symbol?

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

Who are Biogen's major shareholders?

Biogen's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.71%), State Street Corp (4.75%), Geode Capital Management LLC (2.20%), Bank Julius Baer & Co. Ltd Zurich (1.44%), Clearbridge Investments LLC (1.26%) and Northern Trust Corp (1.10%). Insiders that own company stock include Alfred Sandrock, Brian S Posner, Ginger Gregory, Michel Vounatsos, Priya Singhal and Susan H Alexander.
View institutional ownership trends
.

How do I buy shares of Biogen?

Shares of BIIB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biogen's stock price today?

One share of BIIB stock can currently be purchased for approximately $257.52.

How much money does Biogen make?

Biogen (NASDAQ:BIIB) has a market capitalization of $37.29 billion and generates $9.97 billion in revenue each year. The biotechnology company earns $3.05 billion in net income (profit) each year or $18.37 on an earnings per share basis.

How many employees does Biogen have?

The company employs 8,725 workers across the globe.

Does Biogen have any subsidiaries?
The following companies are subsidiares of Biogen: BIIB Colombia S.A.S., Biogen (Argentina) SRL, Biogen (Bermuda) Technologies Ltd., Biogen (Czech Republic) s.r.o., Biogen (Denmark) A/S, Biogen (RTP) Realty LLC, Biogen Australia PTY Ltd, Biogen Austria GmbH, Biogen B.V., Biogen Belgium N.V./S.A., Biogen Biotechnology (Shanghai) Co. Ltd, Biogen Brasil Produtos Farmaceuticos LTDA, Biogen Canada Inc., Biogen Chesapeake LLC, Biogen Chile Spa, Biogen Digital Health Inc., Biogen Estonia OU, Biogen Finland OY, Biogen Foundation Inc., Biogen France S.A.S., Biogen GmbH, Biogen Holding I LLC, Biogen Holding II LLC, Biogen Hong Kong Limited, Biogen Hungary KFT, Biogen Idec (Ireland) Ltd., Biogen Idec Biotech India Pvt. Ltd., Biogen Idec Limited, Biogen Idec Research Ltd., Biogen Idec Uruguay SA, Biogen International GmbH, Biogen International Holding Limited, Biogen International Neuroscience GmbH, Biogen Italia S.R.L., Biogen Japan Ltd., Biogen Korea LLC, Biogen Latvia SIA, Biogen Lithuania UAB, Biogen Luxembourg Holding S.a.r.l., Biogen MA Inc., Biogen Management Services GmbH, Biogen Manufacturing Holding LLC, Biogen Mexico S. DE R.L. DE C.V., Biogen NZ Biopharma Ltd., Biogen Netherlands B.V., Biogen New Ventures Inc., Biogen Norway AS, Biogen Pharma d.o.o., Biogen Pharma farmacevtska in biotehnoloska druzba d.o.o., Biogen Poland Sp. z.o.o., Biogen Portugal Sociedade Farmaceutica Unipessoal Lda., Biogen Realty Corporation, Biogen Realty Limited Partnership, Biogen SRO Inc., Biogen Slovakia s.r.o., Biogen Spain S.L., Biogen Sweden AB, Biogen Swiss Investments GmbH, Biogen Swiss Manufacturing GmbH, Biogen Switzerland AG, Biogen Switzerland Holdings GmbH, Biogen Taiwan Limited, Biogen Therapeutics Inc., Biogen Turkey Ilac Ticaret Limited Sirketi, Biogen U.S. Corporation, Biogen U.S. Limited Partnership, Biogen U.S. Pacific LLC, Biogen U.S. West Corporation, Conforma Therapeutics, Conforma Therapeutics Corporation, Convergence Pharmaceuticals, Convergence Pharmaceuticals Holdings Ltd., Convergence Pharmaceuticals Limited, Eidetica Biopharma GmbH, Fumapharm, IDEC Pharmaceuticals Corporation, NightstaRx Limited, Nightstar Europa Limited, Nightstar Inc., Nightstar Therapeutics Limited, Nightstar Therapeutics plc, Old Convergence Pharmaceuticals Limited, Panima Pharmaceuticals AG, Silver Acquisition Co. Ltd., Stromedix Inc., Stromedix Inc., Syntonix Pharmaceuticals Inc., TYSABRI, and Tungsten Bidco Limited.
Read More
How can I contact Biogen?

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The official website for the company is www.biogen.com. The biotechnology company can be reached via phone at (617) 679-2000, via email at ir@biogen.com, or via fax at 617-679-2617.

This page (NASDAQ:BIIB) was last updated on 9/28/2023 by MarketBeat.com Staff

My Account -